UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON
D.C. 20549
_______________________
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
Report (Date of earliest event reported): December 15, 2009
ADVAXIS,
INC.
(Exact
name of registrant as specified in its charter)
Delaware
(State or
other jurisdiction of incorporation)
|
00028489
|
02-0563870
|
|
(Commission
File Number)
|
(IRS
Employer Identification Number)
|
Technology
Centre of New Jersey
675
Rt. 1, Suite B113
North
Brunswick, N.J. 08902
(Address
of principal executive offices)
Registrant’s
telephone number, including area code: (732) 545-1590
Not
applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
8.01. Other Events.
On
December 15, 2009, Advaxis, Inc. (the “Company”) issued a press release
regarding its planned collaboration with the National Cancer Institute’s Gynecological Oncology Group in a Phase
II clinical trial of the Company’s drug candidate ADXS11-001. A copy
of the press release, which is attached as Exhibit 99.1 to this Current Report,
is incorporated herein by reference.
Item
9.01 Financial Statements and Exhibits.
|
99.1
|
Advaxis,
Inc. press release, dated December 15,
2009.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| Dated: December
15, 2009 |
Advaxis, Inc. |
|
| |
|
|
|
| |
By:
|
/s/ Thomas
A. Moore |
|
| |
|
Thomas
A. Moore |
|
| |
|
Chief
Executive Officer
|
|
| |
|
|
|
EXHIBIT
INDEX
|
Exhibit
No.
|
Document
Description
|
|
99.1
|
Advaxis,
Inc. press release, dated December 15,
2009.
|